While Psychogenics will evaluate Cephalon’s compounds, either firm has the right to further development.
PsychoGenics entered into a drug discovery agreement with Cephalon related to neuropsychiatric disorders. Cephalon will provide related compounds, while Psycogenics will evaluate these candidates.
The companies will jointly identify those candidates suitable for clinical development. If either company decides to further develop any of these drugs, that firm will pay the other milestone and royalty fees .
PsychoGenics’ technologies combines in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics. The platform is used to evaluate potential therapies related to a number of neuropsychiatric disease indications.
